Alcon today announced that it has completed its purchase of Aerie Pharmaceuticals Inc. in a deal that will bolster the company’s presence in the ophthalmic pharmaceutical space with the growing portfolio of commercial products and development pipeline.

Through the transaction, Alcon has added the commercial products netarsudil and latanoprost ophthalmic solution 0. 02%/0. 005%  (Rocklatan) and netarsudil ophthalmic solution) 0. 02%,   (Rhopressa ) as well as AR-15512, a Phase 3 product candidate for dry eye disease. Alcon has also acquired a pipeline of ophthalmic pharmaceutical product candidates with the opportunity to leverage Aerie’s existing research and development capabilities.

“As we welcome the Aerie team to Alcon, we look forward to leveraging our expanding industrial footprint plus expertise to bring Rocklatan  and Rhopressa  to even more customers plus their patients, ” said David Endicott, CEO associated with Alcon. “Alcon has a rich history within the ophthalmic pharmaceutical room rooted in a deep understanding of Eye Care Professionals. We are excited in order to add Aerie’s significant technical expertise to Alcon R& D, which enhances our own efforts in order to build the compelling profile of ophthalmic pharmaceuticals. ”

The transaction also complements Alcon’s expansion into the particular ophthalmic pharmaceutic space, including acquisitions of the exclusive U. S. commercialization rights for Simbrinza  from Novartis in April 2021 and Eysuvis  plus Inveltys  from Kala Pharmaceutical drugs, Inc. in May 2022.

Alcon intends to fully integrate Aerie into its business. As previously disclosed, the company has used debt to fund the transaction for a total purchase consideration of approximately $930 million.

J. P. Morgan acted as Alcon’s financial advisor for the particular transaction, and Alcon’s legal advisor was Skadden, Arps, Slate, Meagher & Flom LLP. Goldman Sachs & Co. LLC and Lazard acted as Aerie’s financial advisors with regard to the deal, and Aerie’s legal advisor was Fried, Frank, Harris, Shriver & Jacobson LLP.

References

  1. Ophthalmology Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030.

Leave a Reply

Your email address will not be published. Required fields are marked *